Helios Cardio

Helios Cardio is a cardiac repair and regeneration company developing biologic tissue scaffolds and therapeutic devices for challenging cardiovascular conditions. The company focuses on chronic heart failure, post-surgical complications, and cardiac repair indications with unmet clinical needs. The core technology platform is Fetal Engineered Biologic Matrix (f-EBM), a tissue scaffold combining mechanical strength with a cell-friendly environment to support cardiac tissue regeneration. Their lead product, CardiaMend™ Pericardial and Epicardial Reconstruction Matrix, is FDA-cleared for pericardial and epicardial repair and reconstruction. CardiaMend™ is based on f-EBM and provides mechanical support while facilitating tissue integration and regeneration. Helios Cardio is investigating f-EBM as both monotherapy (e.g., ventricular restraint in heart failure) and in combination with cellular therapies (autologous or induced pluripotent stem cells) and pharmacotherapies. The company is led by a team with 20+ years of regenerative medicine experience and is advised by cardiac surgeons active in clinical research. Products address coronary heart disease, heart failure, and post-operative atrial fibrillation—conditions affecting millions of patients with significant annual mortality and healthcare costs.